and oral solution. Until recently, there were only human-approved formulations, which were used extra-label in animals (Davis & Maxwell, 2018) . Because of the elevated cost of the human product, attempts to use more cost-effective formulations in veterinary medicine, such as compounded formulations, have been attempted. However, these formulations have shown to present poor systemic absorption and their use in animals is not recommended (Mawby, Whittemore, Fowler, & Papich, 2018; Mawby, Whittemore, Genger, & Papich, 2014; Smith, Papich, Russell, & Mitchell, 2010) . Late in 2016, the FDA approved a veterinary oral itraconazole solution formulation (Itrafungol, 10 mg/ml, Elanco US Inc., Greenfield, IN) for the treatment of dermatophytosis caused by Microsporum canis in cats. This product is identical to the human oral solution with the added benefit of a lower cost compared to the human product.
Although empirical dosages of itraconazole for different avian species are available, pharmacokinetic studies evidence that itraconazole dosages vary between different bird species and absorption fluctuates when using different itraconazole formulations (Bunting et al., 2009; Keller, 2011; Krautwald-Junghanns et al., 2015) . The objective of this study was to investigate the pharmacokinetics of this new veterinary formulation of itraconazole in an avian species commonly found in zoos in order to provide more accurate guidelines for clinical dosages.
| MATERIAL S AND ME THODS

| Animals
In this study, seventeen hand-reared lesser flamingos (eight females and nine males, aged 1-5 years old) with a mean body weight of 1.46 ± 0.14 Kg (median: 1.48 Kg; range: 1.24-1.66 Kg) were sampled after medication administration. Prior to the study, a group of nineteen lesser flamingos were transferred from their exhibit the veterinary hospital. The flamingos were divided into four groups (three groups of 5 and one group of 4) and held in four different stalls measuring 4.1 m × 4.1 m. with rubberized floors. To reduce trauma to the wings during capture and handling, the walls of each stall were padded with foam measuring 1.5 inches thick and 37.5 inches high. Humidity and temperature were not controlled during the time of the study. Flamingos were provided a commercial flamingo feed in black rubber tubs with fresh water as part of their normal diet. Routine husbandry practices were used throughout the study; therefore, no food or water was withheld. This study protocol was reviewed and approved by the Institutional Animal Care and Use Committee at Fort Worth Zoo.
| Procedure
Seventeen birds were designated study participants, and two birds were available as alternates. The birds were chosen based on unremarkable medical history. A 24-hour acclimatization period was allowed prior to drug administration. During transportation to the hospital (24 hr prior to the administration of the drug), a health examination was performed on all animals, and in a random representative population of birds in the study, blood samples were collected for a complete blood cell count and serum biochemical analysis for health screening purposes. Results of the health examinations and bloodwork on selected animals revealed no abnormalities.
The recently approved veterinary oral solution (Itrafungol) was utilized in this study. In addition to the active substance, this formulation contains several excipients including hydroxypropyl-β-cyclodextrin which improves solubility and oral absorption of itraconazole. A single dose (10 mg/kg) of the solution was administered orally to each bird using a gavage needle size 10 and 5 CC syringes.
| Collection of blood samples
Blood was collected from the right jugular vein on all flamingos using a 3-ml syringe with 25-g needle. Between 1.5 and 2.5 ml, blood was collected at each time point. In the case of hematoma formation, subsequent blood samples were collected from the right or left tarsal vein. Any bird with hematoma formation was ad- 
| Analysis of itraconazole concentrations
Itraconazole in plasma was quantified using HPLC with a validated assay in investigator's laboratory. The assay was based on previous work in our laboratory on cats, dogs, penguins, and horses (Davis, Salmon, & Papich, 2005; Hasbach, Langlois, Rosser, & Papich, 2017; Mawby et al., 2014 Mawby et al., , 2018 Smith et al., 2010) . To perform a partial validation for this flamingo study, blank plasma pooled from untreated flamingos was fortified with itraconazole and tested at three concentrations (low, medium, and high) to ensure that the assay met our acceptance criteria. Blank plasma from untreated flamingos was used for quality control samples and calibration standards. Seven calibration standards for the calibration curve ranged from 0.05 to 10 μg/ml. Fresh calibration standards were prepared for each day's analysis. The calibration curve was linear with a R 2 value of at least 0.99. Blank samples (plasma collected prior to drug administration)
were analyzed to ensure that there were no interfering peaks in the chromatogram. There is an active metabolite of itraconazole, hydroxy itraconazole, but it was not measured in this study because we have not found it in our other studies, and only itraconazole is used for predicting therapeutic efficacy (Ashbee et al., 2014; Goodwin & Drew, 2008) .
| Pharmacokinetic analysis
A naïve pooled analysis using a two-compartment model was used to obtain initial estimates (results not shown). From these initial estimates, a one-compartment pharmacokinetic model with first-order absorption was fitted to the data using nonlinear mixed-effects modeling (NLME) (Phoenix NLME ™ version 7.0, Certara Inc., St. Louis, Missouri). The NLME approach accounts for fixed effects for the population and random effects attributed to inter-individual variability. 
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Sparse sampling was performed on the subjects of this study with one, two, or three samples collected per flamingo. Various models were tested with different error structures to determine the best fit base model. The models were parameterized as described above after testing other models. The models were run with the first-order conditional estimation-extended least squares (FOCE-ELS) engine in Phoenix. Model selection was based on goodness of fit plots, diagnostic plots of residuals, scatter plots of predicted vs. observed values, and statistical significance between models using -2LL (twice the negative log likelihood), Akaike information criterion (AIC), purchased in Phoenix. Both fixed effects (parameter values typical for the population) and random effects (a measure of inter-individual or between-subject variability) were estimated from the model. A multiplicative model was used to describe the residual random variability of the data for the residual intra-subject (within-subject) variability.
| RE SULTS
| Animals
No adverse effects were noted in any flamingo due to handling, drug dosing, or sample collection; all birds were returned to their exhibit uneventfully.
| Pharmacokinetics
Itraconazole was detected in all samples from all treated animals.
The population-based pharmacokinetic parameters determined by the NLME are summarized in Table 2 . Plasma drug concentrations are shown for each sampling time point and the average for the entire group in Figure 1 . Also shown in Figure 1 is the fitted line based on the typical pharmacokinetic values for the population listed in Table 1 . As seen in the figures, the terminal concentrations that form the terminal slope were highly variable among flamingos (large inter-individual variation). This caused a high value for the random source error for the elimination rate constant ( Table 2 ).
The pharmacokinetic fit showed an observed improvement in the model after accounting for between-subject variability (data supplied in Figures S1-S2 ). The diagnostic plots showed that after the betweensubject differences are accounted for, there is large improvement compared to the predicted vs. dependent variable (PRED vs. DV) plot.
Plasma concentrations (C MAX ) in lesser flamingo after oral administration of itraconazole solution reached a value of 1.69 μg/ml. Mean area under the curve (AUC) for the plasma concentration vs. time profile was 192.58 μg hr/ml, and elimination half-life was 75.71 hr (Table 2) .
| D ISCUSS I ON
A population pharmacokinetic approach using a sparse sampling strategy was used to minimize stress and blood loss in Itraconazole absorption from the gastrointestinal tract is limited by its low solubility. The oral solution is formulated in β-cyclodextrin to maintain solubility and improve absorption. In previous studies in our laboratory, we found that the oral solution is absorbed 3-5× better in cats than the oral capsule (Mawby et al., 2018) . With exception of one report (Smith et al., 2010) , most of the published itraconazole studies in birds evaluated the pharmacokinetic of the oral capsule formulation. Administration methods requiring granules to be dissolved in acid and gavaged with orange juice and food, granules in orange juice, or capsules placed directly in fish were utilized, which produced different plasma and tissue concentrations (Bunting et al., 2009; Jones, Orosz, Cox, & Frazier, 2000; Lumeij, Gorgevska, & Woestenborghs, 1995; Orosz, Schroeder, Cox, Doss, & Frazier, 1995; Orosz et al., 1996; Tell et al., 2005) . The oral formulation used in this study has distinct advantages, such as ease of administration and cost, over those administration methods.
In our study, we found a higher C MAX and AUC compared to the absorption of a commercial itraconazole product in black-footed penguins (Spenhiscus demersus). However, this is not a direct comparison because the dose was different (7 mg/kg administered with fish) (Smith et al., 2010) , and the mass and body weight of the two species Orosz et al., 1995 Orosz et al., , 1996 Smith et al., 2010; Tell et al., 2005) . The reason for the longer half-life is undetermined. Previous studies have demonstrated that drug distribution patterns differ between avian species due to anatomic and physiologic differences in the avian gastrointestinal tract, particularly different crop and gastric pH between avian groups (Jones et al., 2000; Orosz et al., 1995 Orosz et al., , 1996 .
The lesser flamingo is a filter-feeding species. In captivity, they are fed a variety of commercially available diets. If oral capsules are used for dosing these birds, it could produce wide variation in oral absorption.
Adequate itraconazole plasma concentrations in birds for the treatment of Aspergillus have been assessed using reported minimal inhibitory concentrations (MIC) of itraconazole for different isolates from people (Bunting et al., 2009; Jones et al., 2000; Orosz, 2000) .
The MIC 90 of itraconazole for avian Aspergillus fumigatus isolates was 0.5 ug/ml (Beernaert et al., 2009 ). In people, trough serum itraconazole concentrations of at least 0.5-1.0 ug/ml, measured by HPLC, have been associated with therapeutic success (Ashbee et al., 2014; Goodwin & Drew, 2008) .
In this study, plasma drug concentrations of itraconazole were maintained in a population of flamingos above this minimum concentration for at least 24 hr after a single oral dose of 10 mg/kg of itraconazole solution (Figure 1 ).
Based on the long half-life measures in this study (75 hr) and high peak (1.7 μg/ml), it is likely that lower doses and/or longer treatment intervals would achieve these goals in lesser flamingos. The main limitation of this study was that points were not collected long enough to account for the long half-life of 75 hr.
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